Vir Biotechnology Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / 11:45PM GMT
Eric Joseph J.P. Morgan Securities LLC-Moderator

Okay. Great. Good afternoon. I'm Eric Joseph, senior biotech analyst with J.P. Morgan. And our next presenting company is Vir Biotechnology. And to start the presentation this afternoon is CEO, Marianne De Backer. There is a Q&A session after the presentation. (Conference Instructions) With that, Marianne, thanks for joining us.

Marianne De Backer - Vir Biotechnology Inc - Chief Executive Officer, Director

Okay. Thank you. Thank you, Eric, and thank you, J.P. Morgan, for hosting Vir Biotechnology. Good afternoon, everyone, here in the room in San Francisco and everyone joining on the webcast. I'm Marianne De Backer, and I'm the CEO of Vir Biotechnology.

So 2024 is poised to be a truly transformational year for Vir because we are looking forward to data readouts from our clinical Phase 2 hepatitis delta program, our clinical Phase 2 hepatitis B program and our Phase 1 HIV T cell-based vaccine program. During this presentation, I will share more about Vir's leading clinical programs, about our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot